CTSO - רווח נקי למניה (EPS TTM) CytoSorbents Corp.

Analyzing the annual net income per share for Cytosorbents (CTSO) on GURU.Markets, we note that the current metric is -5.75, confirming the resilience of the strategy. Cytosorbents (CTSO) minimizes risks by outsourcing the production of simple plastic parts to third-party plants. High-margin cartridges produced on automated lines ensure a stable income stream. Blood purification technologies for intensive care units create a solid foundation of recurring customers.

Investors must find a balance between operational risks and the actual return on capital. Cytosorbents controls polymer synthesis, minimizing dependence on third-party housing manufacturers. Earnings per share over the last 12 months reflect the net residual funds attributable to a single share per year. The trend of this metric demonstrates the efficiency of resource allocation and cost management. Stable growth confirms the resilience of the business model.